• Free Book
  • Store
    • Books
    • Free First Chapters
    • Free Newsletters
  • Recent Articles

TradingMarkets.com

Quantified Stock Market Trading Strategies & Systems

  • Home
  • New Trading Research
  • Education
    • Articles
      • Connors Research
      • ETFs
      • Options
      • Stocks
      • Volatility
    • Trading Lessons
    • Connors Research
    • Glossary
    • Interview Archive
    • Videos
  • Python
  • Quantamentals
    • Quantamentals: The Next Great Forefront of Trading and Investing
    • Quantamentals Resources
  • Courses
  • Store
    • New Book! The Alpha Formula
    • “Buy The Fear, Sell The Greed” – Best Seller!
    • Swing Trading College 2019
    • Trading Books and Guidebooks
    • Street Smarts
    • Online Trading Courses
    • Private Mentoring with Larry Connors
    • Customized Trading Research
    • Amibroker Strategy Add On Modules
You are here: Home / Archives for Paul Ruggieri

These 8 Biotechs Are In This Week’s Spotlight

June 16, 2003 by Paul Ruggieri

This week, the annual meeting of the American Diabetes
Association should focus the spotlight on many companies
developing new drug treatments for diabetes (see last weekGÇÖs
biotech piece). Diabetes is a growing problem,
particularly in children, and costs this countryGÇÖs healthcare
system billions of dollars. Despite being effective, todayGÇÖs
treatment

Filed Under: Commentary, Recent

Another Medical Conference Friday — Here Are Some Companies To Watch

June 11, 2003 by Paul Ruggieri

The biotechs have experienced a nice run since March, a run fueled by anticipated positive news out of the recent ASCO meeting.-áWell, the meeting did not disappoint the medical profession

Filed Under: Commentary, Recent

Here’s Why I’m Watching These Six Biotech Stocks

June 5, 2003 by Paul Ruggieri

Starting today, the 6th Annual Meeting of the American Society of Gene Therapy begins in Washington, DC, and with it begins more potential trading opportunities. This meeting, although not as popular as ASCO, is sexier than ASCO by way of its content. It brings together scientists and companies to discuss the latest cutting-edge research in gene therapy for a variety of diseases. The presentations at this meeting are pushing the envelope in applying gene therapy to the treatment of disease.

Filed Under: Commentary, Recent

And The Early Winner Is…

June 2, 2003 by Paul Ruggieri

The American Society of Clinical OncologyGÇÖs annual meeting began this past weekend, and so far the early winner appears to be Genentech (DNA), on many fronts.-á

Filed Under: Commentary, Recent

Several Important Meetings Coming Soon — Here’s What I’m Looking At

May 28, 2003 by Paul Ruggieri

Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterdayGÇÖs biotechGÇÖs wild ride.-á The momentum all started last week with GenentechGÇÖs (DNA) release of-á positive phase III data on its new anti-angiogenesis drug.-á The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell.-á The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III

Filed Under: Commentary, Recent

Why Anything Can Happen In Biotech This Week

May 27, 2003 by Paul Ruggieri

It is only four days before the biggest meeting of
cancer specialists in the worldGǪ..and anything can
happen. Last Monday, Genentech (DNA) could not keep its
secret locked up any longer. On Monday morning, the
company fired the first preemptive shot by releasing positive
survival data on its new anti-angiogenesis drug Avastin for
the treatment

Filed Under: Commentary, Recent

Is There More To Come From These Companies?

May 20, 2003 by Paul Ruggieri

Will yesterdayGÇÖs wild ride for Genentech end?-áYesterday, the company initiated a preemptive release of crucial phase III data on its developing anti-angiogenesis drug Avastin a week before the start of this yearGÇÖs ASCO meeting.-áIt was a thing of beauty and caught everyone off gu

Filed Under: Commentary, Recent

Four Big Stocks To Watch Before A Big Meeting

May 19, 2003 by Paul Ruggieri

The 39th annual gathering of the American Society of Clinical Oncology (ASCO) is only eleven days away (May 31 to June 3) and already Wall Street speculation is brewing on which company will the toast of the meeting.-áThe ASCO meeting is the largest of the year for cancer specialists to present

Filed Under: Commentary, Recent

Why Genentech Is In Play Today

May 19, 2003 by Paul Ruggieri

Genentech announced this morning before the bell that a Phase III trial testing their new drug Avastin with chemotherapy improved overall survival in previously untreated patients with metastatic colorectal cancer.-áThis is significant news.-áAvastin is a monoclonal antibody aimed at a

Filed Under: Commentary, Recent

FDA Panel Decision Is Good For These Three Stocks

May 16, 2003 by Paul Ruggieri

After trading hours yesterday, an FDA Advisory panel unanimously approved a novel approach to treating asthma, a disease that affects millions of people worldwide. Genentech (DNA), Novartis (NOV), and the small biotech

Filed Under: Commentary, Recent

  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »

Buy The Fear, Sell The Greed

Buy The Fear, Sell The Greed

Swing Trading College

New Book From Larry Connors and Chris Cain, CMT – "The Alpha Formula; High Powered Strategies to Beat The Market With Less Risk"

We’re excited to announce the release of a new investment book written by Larry Connors and Chris Cain, CMT. The book, “The Alpha Formula; High Powered Strategies to Beat The Market With Less Risk “ combines… Hedge fund legend Ray Dalio’s brilliant insight into combining uncorrelated strategies… With new, minimally correlated, quantified, systematic strategies to trade… [Read More]

Buy The Alpha Formula Now

Connors Research Traders Journal (Volume 57): 7 Real-World Reasons Why Short Strategies Should Be Included In Your Portfolio

In our new book, The Alpha Formula – High Powered Strategies to Beat the Market with Less Risk, we show the benefits of including short-strategies in your portfolio. As a reminder, building portfolios should be based on First Principles – otherwise known as truths. These truths are: Markets Go Up Market Go Down Markets Go… [Read More]

Company Info

The Connors Group, Inc.
185 Hudson St., Suite 2500
Jersey City, NJ 07311
www.cg3.com

About Us

About
Careers
Contact Us
Link To Us

Company Resources

Help
Privacy Policy
Return Policy
Terms & Conditions

Properties

TradingMarkets
Connors Research

Connect with TradingMarkets

Contact

info@cg3.com
973-494-7311 ext. 628

Free Book

Short Term Trading Strategies That Work

© Copyright 2020 The Connors Group, Inc.

Copyright © 2023 · News Pro Theme on Genesis Framework · WordPress · Log in